Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Our current treatment paradigm of advanced anaplastic lymphoma kinase fusion (ALK+) non-small cell lung cancer (NSCLC) classifies the six currently approved ALK tyrosine kinase inhibitors (TKIs) into three generations. The 2nd-generation (2G) and 3rd-generation (3G) ALK TKIs are all “single mutant a...

Full description

Bibliographic Details
Main Authors: Sai-Hong Ignatius Ou, Misako Nagasaka, Danielle Brazel, Yujie Hou, Viola W. Zhu
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Translational Oncology
Subjects:
TPX-0131
NVL-655
“Single mutant active”
“Double mutant active”
ALK+ NSCLC
Anaplastic lymphoma kinase tyrosine kinase inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321001832

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321001832

Similar Items